Organogenesis Reports Record 2025 Revenue, Forecasts Significant 25-38% Decline in 2026 Revenue

summarizeSummary

Organogenesis reported record net product revenue and strong profit growth for Q4 and FY 2025, but issued a significantly negative revenue guidance for FY 2026, projecting a 25-38% decline due to CMS payment reforms.

check_boxKey Events

• Record 2025 Financial Performance

  The company reported record net product revenue of $225.1 million for Q4 2025 (up 78% year-over-year) and $563.0 million for FY 2025 (up 17% year-over-year). Net income for Q4 2025 increased to $43.7 million from $7.7 million in Q4 2024, and for FY 2025, it rose to $37.0 million from $0.9 million in FY 2024.

• Significant 2026 Revenue Decline Forecast

  Organogenesis projects total net revenue for fiscal year 2026 to be between $350.0 million and $420.0 million, representing a substantial decline of 25% to 38% compared to $564.2 million in FY 2025.

• Impact of CMS Payment Reform

  The projected revenue decline is primarily due to the market adapting to 'sweeping changes from CMS to reform coverage and payment for skin substitutes,' which is expected to impact the first half of 2026.

• Long-Term Growth Expected Post-Transition

  Management expects to drive significant market share gains in the second half of 2026 and return to normalized growth in 2027, following the period of market transition.

auto_awesomeAnalysis

Organogenesis Holdings Inc. delivered strong financial results for the fourth quarter and full fiscal year 2025, achieving record net product revenue and substantial increases in net income and Adjusted EBITDA. However, the company's outlook for fiscal year 2026 is significantly negative, projecting a 25% to 38% decline in total net revenue. This substantial reduction is attributed to market adaptation to sweeping changes from CMS regarding coverage and payment for skin substitutes, creating short-term market confusion. While management anticipates a return to normalized growth in 2027, the immediate forecast of a significant revenue drop is a major concern for investors and will likely pressure the stock.